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ABSTRAK
Tujuan: menganalisis efikasi dan keamanan terapi insulin yang diberikan oleh dokter pada penderita 
diabetes melitus yang tidak terkontrol di pusat layanan kesehatan primer di Surabaya, Jawa Timur, Indonesia. 
Metode: studi pre-post ini melibatkan 99 pasien DM tipe 2 dengan HbA1c >8% yang belum pernah mendapatkan 
terapi insulin sebelumnya. Studi dilakukan pada 10 puskesmas di Surabaya antara Oktober 2011 sampai dengan 
Juni 2012. Terapi insulin diberikan selama 12 minggu. Pemeriksaan laboratorium yang dilakukan pada pasien 
meliputi glukosa darah puasa (GDP), glukosa darah 2 jam post prandial (GD2JPP) dan HbA1c sebelum dan 
sesudah terapi.  Pemeriksaan gula darah mandiri juga dilakukan untuk menyesuaikan dosis insulin dan mencegah 
hipoglikemia. Data dianalisis secara statistik dengan uji T-berpasangan. Hasil: GDP awal adalah 209 mg/dL 
menjadi 152,07 mg/dL pada akhir studi (Δ56,93 mg/dl; p=0,0001) dan GD2JPP juga turun dari 313,00 mg/dl 
menjadi 220,72 mg/dL (Δ 92,28 mg/dl; p=0,0001). HbA1c turun dari 11,60% pada awal studi menjadi 8,95% 
pada akhir studi (Δ 2.65%; p=0,0001). Selama penelitian, hipoglikemia didapatkan pada 6 patients (6,06%) 
dan keseluruhan ringan tanpa membutuhkan perawatan rumah sakit. Kesimpulan: dokter umum pada layanan 
kesehatan primer dapat melakukan inisiasi terapi insulin dengan penurunan HbA1c yang signifikan dan efek 
samping hipoglikemia yang rendah.
Kata kunci: insulin, dokter umum, pusat layanan kesehatan.
ABSTRACT
Aim: to analyze the safety and efficacy of early insulin initiation therapy for patients with type 2 diabetes 
mellitus (T2DM) in primary health care provided by general practitioners (GPs) in Surabaya, East Java, Indonesia. 
Methods: pre-post study of ninety nine diabetic patients without previous insulin treatment with HbA1c levels >8% 
were involved in this study. The study was conducted in 10 primary health care centers in Surabaya between October 
2011 to June 2012. Each patient received insulin therapy for 12 weeks. Laboratory examination was performed for 
each patient including fasting plasma glucose (FPG), 2 hours post-prandial plasma glucose (2hPPG) and HbA1c 
examination before and after the study. Self monitoring blood glucose (SMBG) examination was conducted in 
order to adjust the insulin dose and prevent the incidence of hypoglycemia. Data was statistically analyzed using 
paired-T test. Results: FPG level was decreased from baseline data (209 mg/dL) to 152.07 mg/dL at the end of the 
study (Δ56.93 mg/dl; p=0.0001). The average of 2hPPG level was also decreased from 313.00 mg/dl to 220.72 
mg/dL (Δ 92.28 mg/dL; p=0.0001). HbA1c was reduced from 11.60% at baseline to 8.95% at the end of study (Δ 
2.65%; p=0.0001). Hypoglycemia was found in 6 patients (6.06%)  in this study, but all events were mild and did 
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not need to be admitted to hospital. Conclusion: the safety of insulin therapy iniatiation might be provided by GPs 
at primary health centers with significant efficacy and minimal side effects.
Key words: insulin, general practioner, primary health center.
INTRODUCTION
Type 2 Diabetes Mellitus is a chronic 
metabolic disease with in current prevalence 
a rapid increased. The International Diabetes 
Federation (IDF) estimated the number of 
people with diabetes from 387 million in 2014 
will increase to 592 million in 2035. Indonesia 
has 9.1 million people with diabetes in 2014.1 
World Health Organization (WHO) estimated 
that the number of people with diabetes in 
Indonesia will rise from 8.4 million in 2000 to 
21.3 million in 2030. Central Statistics Agency in 
2003 showed the prevalence of DM was 14.7% 
or about 8.2 million in urban areas and 7.2% or 
about 5.5 million in rural areas. By assuming the 
population growth in 2030, it is estimated that 
DM in urban areas will reach 12 million people 
and in rural areas 8 million people. The report of 
Basic Health Research in 2007 by the Ministry 
of Health showed that the prevalence of DM in 
Indonesian urban areas for ages above 15 years 
was 5.7%.2,3
Data at the Dr. Soetomo Hospital in 
2007 showed that the prevalence of DM who 
underwent hospitalization reached 16.4% with 
a range of complications and mortality reached 
28.8%.4 As the prevalence of DM is increasing, 
it is very important to improve glycemic control 
to delay microangiopathy, neuropathy and other 
complications of diabetes. The United Kingdom 
Prospective Diabetes Study (UKPDS) and other 
studies have shown that intensive glycemic 
control in type 2 diabetes significantly reduces 
the risk of microvascular complications and can 
improve cardiovascular outcomes.5,6
Problems due to poor blood glucose control 
in Indonesia were the reluctance of most of 
patients to start insulin although their blood 
glucose have not been well controlled by 
oral anti-diabetic drugs and reluctance of the 
physicians to provide insulin therapy due to lack 
of knowledge, experience and confidence.7-9 In 
addition, insulin was not well-distributed among 
primary health care services. Patients with 
diabetes who have been poorly controlled with 
oral antidiabetic drugs for years and patients 
with special conditions requiring insulin therapy 
have to go to referral hospital for insulin therapy. 
This policy had lead to the difficulty of patients 
and health care providers in receiving insulin. 
Constraints that arise from GPs at primary health 
center is lack of knowledge about providing 
insulin include indication, dosage, insulin 
regimen selection, SMBG and hypoglycemia 
side-effects treatment. The impact of increasing 
blood glucose is more complications arise. This 
will eventually make the cost higher for treatment 
of DM and its complications.
Another problem is that patients with 
diabetes in secondary and tertiary hospitals are 
stuck due to referrals made by primary health 
care physicians. This will eventually overwhelm 
doctors who work in secondary and tertiary health 
services because of the high ratio of patients per 
doctor. This could be a warning sign to start 
early intensive management of diabetes therapy 
at primary care level. Health care strategy for 
patients with diabetes should be integrated 
into primary health care and hence, the role of 
GPs is crucial. Simple diabetic cases without 
complications can be managed completely by a 
GP, especially if blood glucose levels are well 
controlled. These reasons prompted us to conduct 
a research on the efficacy and safety of insulin 
initiation therapy provided by GPs in patients 
with uncontrolled diabetes mellitus in primary 
health care centers in Indonesia. Results of this 
study will be used to recommend the insulin 




The research was conducted at 10 primary 
health centers in Surabaya between October 
2011 and June 2012. This study was a pre-post 
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study, in which data were collected before 
and after insulin therapy. Insulin therapy was 
performed by GP at related health center who 
had previously received training on insulin 
therapy, for three times face-to-face and regular 
meetings with research assistants every 2 weeks 
to monitor insulin therapy provided by those 
general practitioners. Insulin therapy training 
materials included the using of insulin therapy, 
techniques of insulin injection, side effects 
of insulin therapy, such as hypoglycemia and 
its management, and Self Monitoring Blood 
Glucose (SMBG) examination. The inclusion 
criteria were subjects with Type 2 Diabetes 
Mellitus (T2DM) who had not received insulin 
treatment, subjects with HbA1c levels >8%, and 
subjects who were willing to participate in the 
study by signing informed consent. The exclusion 
criteria included subjects who had insurance 
which requires the concerned to be referred to 
the hospital, subjects who were hypersensitive to 
insulin aspart, insulin detemir, biphasic insulin 
aspart 30 and ingredients of the products, and 
women in pregnancy, breastfeeding or planning 
a pregnancy in the next 6 months period.
In this study, data collection included 
subject’s demographic, weight, duration of 
diabetes, complications and the medication based 
on interview and medical record. The subjects 
were also checked Fasting Plasma Glucose 
(FPG), 2 hours Post Prandial Glucose (2hPPG) 
and Hemoglobin A1c (HbA1c) examination 
on baseline and the end of study. Subjects also 
filled out questionnaires about quality of life 
before and after therapy. Self monitoring blood 
glucose (SMBG) examination was conducted in 
order to adjust the insulin dose and to prevent the 
incidence of hypoglycemia. SMBG monitoring 
was done at waking up in the morning, after 
breakfast, before and after lunch and dinner. 
Monitoring was done every three days. This 
research has been granted permission from the 
ethics committee of the Faculty of Medicine, 
Airlangga University, no. 049/EC/KEPK/
FKUA/2011 dated 2 November 2011.
Data Collection 
This study was a prospective study in which 
the data were documented in Case Record Forms 
(CRF) prepared for each patient. Data were 
obtained through interviews and laboratory tests 
and other data contained in medical records. 
Blood samples for HbA1c examination were 
obtained through blood venous with EDTA 3 ml 
for all subjects recruited and analyzed using High 
Performance Liquid Chromatography (HPLC). 
For patients who have received insulin therapy, 
SMBG was recorded by GPs, and each week they 
met the researchers to report on SMBG recording 
and insulin dose adjustments. Monitoring was 
scheduled for every two weeks.
Study Population
The study was conducted at 10 primary health 
centers in Surabaya, such as Pakis, Manukan 
Kulon, Asem Rowo, Tambak Rejo, Ketabang, 
Mulyorejo, Pacar Keling, Wonokusumo, Takal 
and Sawahan. The primary health centers were 
selected based on geographical distribution and 
high prevalence of DM. Ninety-nine patients 
were recruited between December 2011 - 
February 2012.
Statistical Analysis
Data on subject demographic characteristics 
included age, body mass index, blood pressure, 
and duration of subjects suffering from diabetes 
mellitus, HbA1c, FPG and 2hPPG analyzed 
descriptively by calculating the mean and 
standard deviation, in addition to calculate the 
proportion of subjects, including sex, history of 
medication, side effects, and complications.
To calculate the difference in body mass 
index (BMI), mean HbA1c levels, FPG and 
2hPPG was done before and after insulin therapy. 
Paired T-test was done preceded by normality test 
on data distribution of the two groups data using 
the Kolmogorov-Smirnoff test.
RESULTS
Number of subjects participating in the study 
was 99 with characteristics shown in Table 1. In 
this study, female subjects were more than male 
subjects (80 vs 20%). The mean age of the patients 
was 53.7+9.31 years old, ranging from 33 to 80 
years old. The mean weight of the patients was 
58+10.39 with BMI of 24.44±4.12kg/m2. Mean 
duration of diabetes was 6.2±5.3 years. Most 
of the older patients have been suffering from 
diabetes for 29 years and there were 7 patients 
Vol 47 • Number 2 • April 2015                  Safety and efficacy in early insulin initiation as comprehensive therapy
107
who have been suffering from diabetes for less 
than 3 months before the study (Table 1).
Diabetes Complications
Sixty four subjects had complications, 
with neuropathy as the most common single 
complication. In contrast, cardiovascular disease 
was rarely found as a single complication. 
Sixteen subjects suffered from all of three 
complications and only 35 subjects had no 
complications. (Table 1)
The majority of the subjects (80%) had 
been previously treated with a combination 
of metformin and a sulfonylurea. Six subjects 
received only sulfonylurea, and 7 subjects 
recieved only metformin. Six subjects were 
previously not treated with either metformin or 
sulfonylurea, two subjects used herbal medicines 
and four subjects did not receive treatment at 
all. (Table 1)
Glycemic Control
In this study, 99 subjects of the primary health 
centers received insulin, 79 subjects received 
basal insulin (insulin detemir) in combination 
with the previous oral anti-diabetic drugs, 2 
subjects received premixed insulin (Biphasic 
Insulin Aspart 30), 14 subjects received basal 
plus insulin (insulin detemir and 1-2x insulin 
aspart) and 4 subjects received basal bolus 
insulin (insulin detemir and 3x insulin aspart). 
FPG were significantly reduced 56.93 mg/dL 
(p=0.0001) from baseline (209 mg/dL) to 152.07 
mg/dL at end of the study in 99 patients. Two 
hours post prandial glucose also significantly 
reduced -92.28 mg/dL from 313.00 mg/dL to 
220.72 mg/dL (p=0.0001). In this study, we also 
found a significant decrease of HbA1c from 
11.60% at baseline to 8.95% at the end of the 
study (p=0.0001). Therefore, the mean reduction 
of HbA1c obtained in patients receiving insulin 
was 2.65%. (Table 2)
Hypoglycemic Complications
In this study, hypoglycemia was found in 
6 subjects (6.06%), 4 subjects were receiving 
therapy with insulin detemir, 1 subject was 
receiving a premixed insulin and 1 subject was 
receiving basal bolus therapy. Subjects receiving 
insulin detemir and 1-2 times insulin aspart were 
not having hypoglycemia. All hypoglycemia 
event were mild, subjects treated themselves at 
home, reported to their GP for insulin adjustment 
doses and did not need hospitalization.
DISCUSSION
Many patients with T2DM are in poor 
glycemic control leading to an increase in the 
risk of more severe complications. In this study 
most of patients with T2DM treated in primary 
health centers were uncontrolled. The mean 
HbA1c levels were 11.6%, which was still far 
from the standard recommended by Perkeni 
in 2011 which is below 7%.3 Type 2 diabetes 
is a disease with progressive natural course, 
because pancreatic beta cell function and insulin 
Table 1. Characteristics and patient demographics
Variables n (%) Mean + SD
Total (n) 99 (100%)
Sex:
 - Male (%) 20 (21%)
 - Female (%) 79 (79%)
Age (year) 53.7 + 9.31
Bodyweight (kg) 58 + 10.39
BMI (kg/m2) 24.44 ± 4.12
Type 2 Diabetes Mellitus 
Duration (years)
6.2 + 5.39
HbA1C (%) 11.6 + 2.03
Fasting Blood Glucose 
(mg/dL)
209 + 81.62




 - No complications 35(35,3%)
 - CVD only 1(1%)
 - Eye only 5 (5%)
 - Neuropathy only 21(21,2%)
 - CVD + Eye 2 (2,1%)
 - CVD + Neuropathy 5 (5%)
 - Eye + Neuropathy 14 (14,2%)




 - Sulfonylurea only 6 (6%)
 - Metformin only 7 (7%)
 - Sulfonylurea + 
Metformin
80 (81%)
 - Herbal therapy 2 (2%)
 - No therapy 4 (4%)
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physiological response will decrease over time 
despite good glycemic control management. 
Thus, many patients still require insulin therapy 
whether with the increased dose or additional 
oral diabetic drugs. More than 60% patients with 
T2DM require insulin therapy within 6-10 years 
after the initial diagnosis.8,10 In this study, with an 
average duration of diabetes of 6.2 years, most 
of subjects had already required treatment with 
insulin (Table 1).
Insulin is the most effective therapy to 
achieve glycemic targets. However, there is still a 
reluctance of both doctors and patients to initiate 
insulin therapy. Factors related to the patient’s 
reluctance includes fears of insulin injection, 
insulin addiction, and sometimes skeptical of the 
success of insulin itself, while GP’s reluctance 
includes the fear of side effects of insulin, such 
as hypoglycemia and weight gain, limited time 
for education and training for the patients about 
the use of insulin. Sometimes GPs have lack of 
knowledge for using of insulin itself.11 Another 
important cause is the availability of insulin in 
the primary health centers. Insulin distribution 
did not cover primary health centers in Indonesia.
Poor glycemic control and frequently delayed 
insulin therapy lead to various complications. 
The UKPDS showed that the decrease in HbA1c 
will lower the incidence of complications, both 
microvascular and neuropathic complications.5 
Similar with the UKPDS, this study showed that 
64.5% of patients were having complications 
with a high baseline of HbA1c (11.6%). One 
of these complications, cardiovascular disease, 
retinopathy or neuropathy, was found in 27 
T2DM subjects, while 21 subjects suffered from 
two complications (21.21%) and 16 subjects 
(16.16%) suffered from 3 complications. It 
means that 37.37% of patients with T2DM had 
more than one complications. Similar results 
were found in a multicenter study in the United 
Kingdom by Holman et al who conducted study 
of 708 patients with suboptimal HbA1c levels 
(between 7.0 to 10.0%). They found 17.2% of the 
patients had retinopathy, 19.1% with neuropathy, 
19.5% with macroangiopathy and 9.6% with 
nephropathy.12 This showed that both in modern 
countries like United Kingdom and developing 
countries like Indonesia, the complications of 
diabetes are associated with glycemic control. 
(Table 1)
The study was conducted on T2DM patients 
with poor glycemic control, characterized by 
HbA1c levels of >8%, both in subjects treated 
with and without oral anti-diabetic drugs. Most 
of the subjects (81%) had been treated with 
the combination of oral diabetic drugs such as 
metformin and sulfonylureas available at primary 
health centers. Those who received single oral 
drugs only were 13 (13%) subjects, and 6 (6%) 
subjects had used herbal medicine or never been 
treated at all. (Table 1)
The subjects had significant improvement 
in glycemic control after being treated with 
insulin, both in FPG and HbA1c in all groups 
that received either basal insulin (insulin detemir) 
alone, premixed insulin, basal plus (combination 
of insulin detemir + insulin aspart 1-2 times) and 
basal bolus (insulin detemir combination + 3 
times insulin aspart). Overall reduction of HbA1c 
was 2.65% from 11.60% at baseline to 8.95% 
at the end of study. The mean FPG decline was 












Δ p Pre Post Δ p
Total 99 209.00 152.07 56.93 0.0001 313.00 220.72 92.28 0.0001 11.60 8.95 2.65 0.0001
Detemir 79 206.96 147.46 59.50 0.0001 292.80 207.43 85.37 0.0001 11.56 8.75 2.81 0.0001
Basal 
Plus 14 202.21 148.64 53.57 0.397 345.84 228.06 117.80 0.004 11.52 9.65 9.65 0.011
Basal 
Plus 4 261.50 213.50 48.00 0.237 237.50 244.50 -7.0 0.469 12.83 11.43 1.47 0.359
Premix 2 125.00 80.50 44.50 0.296 446.50 135.00 311.5 0.303 11.80 7.55 4.25 0.366
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56.93 mg/dL and the mean decline in 2hPPG was 
92.28 mg/dL. The highest reduction of HbA1C 
and 2hPPG was obtained in the premixed insulin 
group (4.25% and 311.5 mg/dL respectively). 
However, patients who received premixed 
insulin were only 2 people. The highest FPG 
reduction was obtained in the insulin detemir 
group, which was 59.59 mg/dL. (Table 2)
This study showed better results compared 
to previous studies conducted. Hermansen et al 
studied 476 patients with HbA1c ranged from 
7.5 to 10.0% and he found that additional insulin 
detemir on oral anti-diabetic drugs therapy for 24 
weeks decrease HbA1c from baseline to 1.8%.13 
A study by Rosenstock showed that patients 
treated with insulin detemir showed decrease of 
HbA1c from baseline to 1.4% after 52 weeks of 
insulin therapy and a decline of FPG from 10.8 
mmol/L to 7.1 mmol/L.14 A study by Holman 
et al revealed a 0.8% reduction of HbA1c with 
basal insulin alone (insulin detemir), 1.3% with 
biphasic insulin (premix) and 1.4% with prandial 
insulin (insulin aspart) alone12, while the research 
by Liebl et al.15 using basal-bolus insulin and 
biphasic insulin (premix) found a 1.56% and 
1.23% decrease of HbA1c.15 Regarding these 
facts, this study showed decrease of HbA1c, 
which was very likely because the baseline 
HbA1c levels in this study was as high as 11.6% 
in health centers.
The episode of hypoglycemia was found only 
in 6 (6.06%) patients, and all were mild episodes, 
which only required insulin dose adjustment and 
not requiring hospital treatment. No other side 
effects were found in this study, such as allergic 
or local reactions at the site of injection, quite 
similar with the study by Hollander et al. who 
reported that hypoglycemia was as high as at 
4.7%, and the adverse events (AE) were found in 
86.4% of patients (185/214 patients).16 Holman et 
al.12 showed that in patients with insulin detemir 
alone, three times mealtime insulin aspart and 
biphasic insulin resulted mean hypoglycemic 
events per patient per year of 2.3; 12.0 and 5.7.
Considering that the significant decrease of 
HbA1c level and hypoglycemia episodes that 
were not much different from other previous 
studies, it is suggested that GPs in health centers 
Surabaya were competent to initiate insulin 
therapy for type 2 diabetes mellitus patients with 
poor glycemic control.
CONCLUSION
Despite getting oral anti-diabetic drugs 
therapy for several years, most patients with type 
2 diabetes in primary health care centers had poor 
glycemic control which was shown by their high 
average of HbA1c and blood glucose level. This 
study also showed that insulin therapy could 
significantly control blood glucose levels. It was 
indicated by decreased level of HbA1c among 
patients with either basal, biphasic (premixed), or 
combination of basal and insulin-plus basal-bolus 
additional insulin therapy. All subjects turned 
out to have a significant reduction in HbA1c 
levels. General practitioners at health centers can 
perform insulin therapy after obtaining training 
and the provision of sufficient material regarding 
insulin therapy. General practitioners at health 
center level are competent to perform insulin 
therapy indicated by a significant decrease in 
HbA1c levels and the low rate of hypoglycemic 
incidence among patients with additional insulin 
therapy performed by GPs involved in this study. 
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